Traders should monitor mid-2026 for initial STRO-004 clinical data, which could serve as a major value catalyst. The improved financial efficiency and extended cash runway reduce near-term dilution risk and support continued development of Sutro’s high-potential dual-payload ADC platform.
Price Chart
Executive Summary
Sutro Biopharma reported its 2025 financial results, highlighted by a 65% year-over-year increase in revenue to $102.5 million, primarily from its Astellas and Ipsen collaborations, while significantly reducing R&D and G&A expenses. The company also announced clinical progress across its ADC pipeline, including dosing in a Phase 1 trial for STRO-004 and advancement of its dual-payload programs, supported by a $110 million capital raise extending its cash runway into Q2 2028.
Key Financial Metrics
Key Facts
- Revenue increased 65% YoY to $102.5 million in 2025, up from $62.0 million in 2024, driven by collaboration income from Astellas and Ipsen.
- Total operating expenses dropped from $300.5 million in 2024 to $260.9 million in 2025, with R&D spending down 34% despite ongoing clinical development.
- Cash, cash equivalents, and marketable securities totaled $141.4 million as of December 31, 2025, and a $110 million equity raise extended the cash runway into at least Q2 2028.
- STRO-004 Phase 1 trial completed dosing in three cohorts, with initial clinical data expected mid-2026.
- STRO-227, a dual-payload ADC targeting PTK7, remains on track for IND submission in 2026.
- Astellas began patient dosing in a dual-payload iADC trial, triggering a $10 million milestone expected in Q2 2026, and a second program triggered a $7.5 million payment in late 2025.
Financial Impact
Revenue increased by $40.5 million YoY while reducing operating expenses by $39.6 million, improving financial efficiency. The $110 million capital raise significantly extends operational runway.
Risk Factors
- As a clinical-stage company, Sutro remains dependent on clinical trial outcomes, which are inherently uncertain.
- Future revenue is heavily tied to collaboration milestones, which may be delayed or not achieved.
- The company has a stockholders' equity deficit of $132.5 million, indicating ongoing reliance on external financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260829 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.35 (−27.93%) |
Aug 12, 2026 7w ago | Press Release | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.35 (−27.93%) |
Apr 22, 2026 23w ago | DEFA14A | $34.83 $31.13 | ▼ −10.62% | ▼ −15.26% | $15.35 (−55.93%) |
Apr 19, 2026 23w ago | Press Release | $34.58 $34.48 | ▼ −0.29% | ▼ −4.49% | $15.35 (−55.61%) |
Mar 23, 2026 27w ago | S-3 | $23.57 $35.53 | ▼ −50.74% | ▼ −41.84% | $15.35 (+34.87%) |
Mar 23, 2026 27w ago | Press Release | $23.57 $35.53 | ▲ +50.74% | ▲ +41.84% | $15.35 (−34.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access